Mankind Pharma Limited has informed the Exchange regarding Appointment of Mr Satish Kumar Sharma as Executive Director of the company w.e.f. September 23, 2026.
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Mankind Pharma's Board approved FY2026 results with standalone net profit of ₹713.61 crores on revenue of ₹10,421.18 crores, with an unmodified audit opinion. The Board re-appointed Mr. Satish Kumar Sharma as Whole-Time Director for 5 years from September 23, 2026, subject to shareholder approval. Mr. Pramod Gokhale, Global CIO, resigned effective May 31, 2026. The company also approved up to ₹500 crores additional investment in its wholly-owned subsidiary Mankind Medicare Private Limited. Key executives (Chairman, VC&MD, CEO) voluntarily declined their commission for FY2025-26 to preserve cash for business expansion.
The resignation of the Global CIO represents a senior management change, though voluntary commission waiver by top executives signals cost discipline. Strong profit growth and continued subsidiary investments indicate ongoing expansion strategy despite macro headwinds.